The field of food allergy therapeutics is continuing to boom as companies flood the news with fresh IND clearances and clinical readouts. The race to market for the next food allergy therapy is well and truly on, but access to funding and large patient cohorts, along with the need for novel IgE biomarkers and better diagnostics (to name a few challenges) are holding drug developers back from even faster progress.

The 2nd Next-Generation Food Allergy Drug Development Summit is reuniting this December as the only industry-focused meeting dedicated to unveiling the complexities of food allergies with novel oral immunotherapies, antibody-based therapeutics and microbiome-based approaches to accelerate ground-breaking treatments for the ever-increasing unmet medical need.

Join us in-person for the first time in Boston as the food allergy community comes together to unravel the complex regulatory landscape, identify and validate novel clinical biomarkers to aid patient selection and explore novel routes of administration to innovate long-lasting, next-generation treatments.

To know more visit: https://bit.ly/3GlzzRp